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Abstract
The pyrrole-imidazole family of marine alkaloids, derived from linear clathrodin-like precursors,
constitutes a diverse array of structurally complex natural products. The bioactive agelastatins are
members of this family that possess a tetracyclic molecular framework incorporating C4–C8 and
C7–N12 bond connectivities. We provide a hypothesis for the formation of the unique agelastatin
architecture that maximally exploits the intrinsic chemistry of plausible biosynthetic precursors.
We report the concise enantioselective total syntheses of all known agelastatin alkaloids including
the first total syntheses of agelastatins C, D, E, and F. Our gram-scale chemical synthesis of
agelastatin A was inspired by our hypothesis for the biogenesis of the cyclopentane C-ring and
required the development of new transformations including an imidazolone-forming annulation
reaction and a carbohydroxylative trapping of imidazolones.
Introduction
The agelastatin alkaloids constitute an intriguing subset of the diverse pyrrole-imidazole
family of marine alkaloids that are likely derived from linear biogenetic precursors such as
clathrodin (7),1 hymenidin (8),2 and oroidin (9, Figure 1).3,4 (–)-Agelastatins A (1) and B
(2) were first isolated from the Coral Sea sponge Agelas dendromorpha by Pietra in 1993
who successfully identified and chemically studied their unique tetracyclic structures.5–8 In
1998, Molinski isolated (–)-Agelastatins C (3) and D (4) from Cymbastela sp. native to the
Indian Ocean.9 Recently, Al-Mourabit has reported the isolation of (–)-Agelastatins E (5)
and F (6) from the New Caledonian sponge Agelas dendromorpha.10 (–)-Agelastatin A (1)
exhibits significant antitumor activity and inhibits osteopontin-mediated neoplastic
transformation and metastasis in addition to slowing cancer cell proliferation by causing
cells to accumulate in the G2 phase of the cell cycle.11,12 (–)-Agelastatin A (1) also exhibits
toxicity towards arthropods,9 and selectively inhibits the glycogen synthase kinase-3β,
which is a potential target for the treatment of Alzheimer’s disease and bipolar disorder.13,14
These properties have prompted considerable efforts toward the total synthesis of agelastatin
A (1), resulting in inventive syntheses from 10 different research groups. In 1999, Weinreb
completed the first total synthesis of agelastatin A (1) employing a key N-sulfinyl dienophile
hetero-Diels–Alder reaction.15,16 Feldman reported the first enantioselective syntheses of
(–)-Agelastatin A (1) and (–)-Agelastatin B (2) using an alkylidenecarbene C−H insertion
reaction.17,18 While Hale applied aziridine opening chemistry to the synthesis of (−)-1,19,20
Davis utilized ring-closing metathesis and N-sulfinyl imine based methodologies to access
(–)-Agelastatin A (1).21,22 Sequential palladium-catalyzed asymmetric allylic alkylation
reactions were key to Trost’s concise total synthesis of (+)-1.23,24 Ichikawa’s sigmatropic
rearrangement of an allyl cyanate25 in addition to Wardrop and Chida’s respective use of the
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Overman rearrangement constituted additional successful approaches to 1.26,27 The interest
in the field has continued with application of aziridination methodologies by Yoshimitsu,
28,29 and most recently by Du Bois’ elegant solution to (−)-1.30 Interestingly, all of these
syntheses have in common an early introduction of the C-ring followed by further
elaboration to afford the desired tetracyclic framework. Additionally, the reported syntheses
of agelastatin A (1) do not specifically evaluate existing hypotheses for biogenesis of its
intriguing molecular architecture. Furthermore, there are currently no total syntheses of
agelastatins C (3), D (4), E (5), or F (6). Herein, we report the first biogenetically inspired
and unified approach to all (–)-Agelastatins (1–6) using a concise synthetic strategy
empowered by the inherent chemistry of potential biosynthetic intermediates.
The agelastatins are the only isolated pyrrole-imidazole alkaloids with C4–C8 and C7–N12
connectivities (Figure 1). Feeding studies by Kerr demonstrated that histidine and ornithine
(or proline) are the amino acid precursors for related pyrrole-imidazole alkaloids.31 There
are currently two reported biosynthetic hypotheses for the agelastatins,5,32 and both suggest
that the formation of the carbocyclic C-ring results from C8-nucleophilic trapping of a C4-
electrophile in a clathrodin derivative. Furthermore, these hypotheses suggest an early stage
biosynthesis of the C-ring followed by B-ring formation and attribute stereochemical control
to the action of putative enzymes.
Results and discussion
Biosynthetic hypothesis and design plan for total synthesis
The fascinating molecular architecture of the agelastatins and interest in evaluating our new
hypothesis for the biogenetic origins of the C-ring involving cyclization with concomitant
introduction of three stereocenters motivated the studies described here. We envisioned an
advanced-stage biosynthetic sequence (Scheme 1) distinct from existing hypotheses that
relies on: 1) reverse polarity in C-ring formation involving C4-nucleophilic trapping of a
C8-electrophile for C-ring formation, 2) introduction of the C-ring after the B-ring
formation, and 3) substrate directed stereochemical control and use of intrinsic chemistry
that is perhaps enhanced by the action of biosynthetic enzymes. Our retrosynthetic factoring
of (–)-Agelastatin A (1) inspired by our retrobiosynthetic analysis of 1 is illustrated in
Scheme 1. Ionization of the C5-hydroxyl of 1 followed by the strategic disconnection of C4–
C8 reveals N-acyliminium ion 17 and clears the carbocyclic C-ring along with three
stereocenters. The mechanistic development of a transform33 linking 1 to 17 prompted
consideration of a versatile precursor, pre-agelastatin A (16, Scheme 1). In the forward
direction, our hypothesis asserts that pre-agelastatin A (16) may be ionized to the C8-
acyliminium ion 17, allowing a 5-exo-trig cyclization followed by C5-hydroxylation to
secure the C4-, C5-, and C8-stereocenters in the final stage of the biosynthesis (Scheme 1,
16→1). We envisioned that pre-agelastatin A (16) would result from C2-hydrolysis and C8-
oxidation of the cyclooroidin analogue 14. Tricycle 14 would be formed by C4-protonation
of linear precursor 11 followed by C7-trapping by the pyrrolyl-nitrogen (N12) via a 6-exo-
trig cyclization.34 Notably, this pathway suggests a link between the agelastatins and the
natural product cyclooroidin (10, Figure 1),35 and is consistent with Lindel’s reported acid
promoted conversion of oroidin (9) to tricycle 10.36 Motivated by the potential direct
conversion of pre-agelastatin A (16) to (–)-Agelastatin A (1), we targeted the related
structure O-methyl-pre-agelastatin A (19) and envisioned its concise synthesis from readily
available D-aspartic acid derivative 22 (Scheme 1, 22→19).
Total synthesis of the agelastatin alkaloids
Our convergent synthesis for the desired O-methyl-pre-agelastatin A (19) commenced with
pyrrole (+)-22 (Scheme 2), accessible in one step from commercially available D-aspartic
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acid dimethyl ester.37 Exposure of pyrrole (+)-22 to N-bromosuccinimide (NBS) in the
presence of 2,6-di-tert-butyl-4-methylpyridine (DTBMP) afforded the bromopyrrole (+)-23
in 92% yield and 99% ee. Treatment of bromopyrrole (+)-23 with chlorosulfonyl isocyanate
afforded amide (+)-24 in 82% yield. Subsequently, addition of sodium borohydride followed
by p-toluenesulfonic acid (TsOH) to a methanolic solution of (+)-24 generated bicycle
(+)-21 as a single diastereomer in 90% yield and 99% ee on greater than 10-gram scale. The
conversion of (+)-24 to bicycle (+)-21 occurs via formation and immediate C8-reduction of
the imide 25, preventing an undesired C7-epimerization.38 Identical B-ring formation with
the desbromopyrrole derivative of 24 resulted in significant erosion of enantiopurity. This
observation was consistent with our postulate that the C7–H bond would be forced to adopt
a pseudo-equatorial conformation to minimize allylic strain between the C13-bromine and
C6-methylene, which suppressed undesired C7-deprotonation. Interestingly, the use of
pyrrole (+)-24, possessing the C13-bromine present in all known agelastatins, provided
chemical reactivity beneficial to our synthetic strategy (vide infra).
We next aimed to develop a general strategy for the introduction of the imidazolone
substructure present in the targeted pre-agelastatin 16.39 Initially, we focused on the direct
addition of transmetallated derivatives of triazone 27 (Scheme 2, metal = Li, Mg, Cu, Ce,
Zn) to the bicyclic C5-ester (+)-21. Unfortunately, these attempts were plagued by either
lack of reactivity, the formation of byproducts associated with metal-halogen exchange,
double addition, or competing decomposition pathways. Furthermore, these metallated40–42
triazone derivatives were generally unstable at temperatures above 0 °C. Thus, the
development of a new strategy for the union of a stable metallated triazone and ester (+)-21
as the prelude to introduction of the imidazolone was necessary.
We envisioned that the cross coupling of thioester derivatives43–45 with stannylurea
derivatives would represent a versatile synthesis of substituted imidazolones. Thioester
(+)-26 was readily prepared in 92% yield through treatment of ester (+)-21 with
trimethylaluminum and 4-methylbenzenethiol in dichloromethane (Scheme 2). The structure
of (+)-26 was secured via X-ray crystallographic analysis,46 revealing the pseudo-equatorial
C7–H bond. After extensive experimentation, we found that the union of thioester (+)-26
with the readily available triazone 2747–49 could be achieved efficiently in the presence of
stoichiometric copper(I)-thiophene-2-carboxylate (CuTC) to give the ketone (+)-28 (96%,
>5g-scale). Exposure of triazone (+)-28 to methanolic hydrogen chloride unraveled the keto-
urea 20, which upon spontaneous condensative cyclization50,51 provided the desired (+)-O-
methyl-pre-agelastatin A (19) in 89% yield with 99% ee (Scheme 2). The structure of (+)-19
was secured via X-ray crystallographic analysis, and its thermal ellipsoid representation
illustrates that the C7-methylimidazolone and C8-methoxy group reside in a pseudo-diaxial
conformation (C6-C7-C8-O8′ dihedral angle of 173°).46
With (+)-O-methyl-pre-agelastatin A (19) in hand, we proceeded to evaluate our hypothesis
for C-ring biogenesis and rapid introduction of the C4-, C5-, and C8-stereocenters.
Gratifyingly, heating an aqueous solution of (+)-19 with methanesulfonic acid provided (–)-
Agelastatin A (1, Scheme 2) as the major product along with (−)-4,5-di-epi-agelastatin A
(structure not illustrated) as the minor stereoisomer (2:1). Monitoring of this reaction by 1H
NMR revealed that (−)-4,5-di-epi-agelastatin A is the kinetic product, which equilibrates to
the thermodynamically favored desired product (–)-Agelastatin A (1), likely via
intermediacy of tetracycle (−)-30. Analysis of the rate of solvolysis of each isomer
illustrated that the C5-hydroxyl of (−)-4,5-di-epi-agelastatin A ionizes significantly faster
than the corresponding C5-hydroxyl of (–)-Agelastatin A (1). In the event, upon complete
consumption of pre-agelastatin A (16), simple exposure of the reaction mixture to methanol
efficiently converted (−)-4,5-di-epi-agelastatin A to (−)-O-methyl-di-epi-agelastatin A (29),
enabling facile separation of (−)-1 and (−)-29 (Scheme 2). Under preparative conditions, our
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putative biomimetic cyclization of (+)-19 afforded (–)-Agelastatin A (1) in 49% yield (1.4 g,
99% ee) along with (−)-O-methyl-di-epi-agelastatin A (29) in 22% yield. This constitutes a
total chemical synthesis of (–)-Agelastatin A (1) in eight steps for the longest linear
sequence from commercially available starting material with 22% overall yield.
Furthermore, resubmission of (−)-29 to the above protocol afforded (–)-Agelastatin A (1) in
66% yield along with recovered (−)-29 (30%) post equilibration. The structure of (−)-1 was
secured through X-ray crystallographic analysis (Scheme 2).46 It should be noted that this 5-
(enolendo)-exo-trig52 type of cyclization with an acyliminium ion is a rare and challenging
reaction as evidenced by the paucity of relevant examples in the literature.53,54 Importantly,
the versatility of our new imidazolone annulation allows for the union of thioester (+)-26
and the simple stannylurea derivative 33 (cHx3SnCH2NH(CO)NHMe) to afford (+)-O-
methyl-pre-agelastatin A (19) without isolation of any intermediates, providing the shortest
total synthesis of (–)-Agelastatin A (1, 7-steps, Scheme 2) to date.
Under optimal conditions, treatment of (–)-Agelastatin A (1) with NBS and DTBMP in a
water–tetrahydrofuran solvent mixture afforded (–)-Agelastatin B (2) in 84% yield.
Interestingly, X-ray crystallographic analysis of (–)-Agelastatin B (2) revealed that its C-
ring conformation is distinct from that of (–)-Agelastatin A (1) as highlighted by the 25° and
31° difference in the C5-C4-C8-N9 and N1-C5-C4-C8 dihedral angles, respectively.46
Importantly, (−)-O-methyl-di-epi-agelastatin A (29) served as a versatile precursor for the
synthesis of (–)-Agelastatin C (3, Scheme 2). Heating a solution of (−)-O-methyl-di-epi-
agelastatin A (29) in pyridine afforded (−)-dehydroagelastatin A (30, Scheme 2) in 99%
yield.55 As anticipated, treatment of 30 with dimethyldioxirane (DMDO) gave (−)-di-epi-
agelastatin C (31, 98%) via oxidation on the convex face. Significantly, heating an aqueous
solution of (−)-di-epi-agelastatin C (31) with BrØnsted acid slowly afforded (–)-Agelastatin
C (3, 41%) along with recovered 31 (42%). We propose that this equilibration occurs via the
intermediate 32 consistent with our observations of deuterium incorporation at the C6-
methylene when using deuterium oxide as solvent.56
Our new imidazolone annulation methodology proved most effective for accessing the
desired pre-agelastatin D intermediate for the first synthesis of (–)-Agelastatin D (4, Scheme
3). Under our optimized conditions, treatment of thioester (+)-26 with stannylurea 34 and
CuTC followed by exposure to methanolic hydrogen chloride afforded (+)-O-methyl-pre-
agelastatin D (35) in 62% yield. Despite the attenuated C4-nucleophilicity of (+)-O-methyl-
pre-agelastatin D (35) compared to (+)-O-methyl-pre-agelastatin A (19) in polar-protic
solvents,57 application of our key cyclization protocol as described above indeed provided
the desired (–)-Agelastatin D (4) in 26% yield along with (−)-O-methyl-di-epi-agelastatin D
(36, 9%).58 The structure of (–)-Agelastatin D (4), secured through X-ray crystallographic
analysis, demonstrated a C-ring conformation similar to (−)-1.46 Despite the success of this
putative biomimetic cyclization, the greater propensity of 35 to undergo competing reactions
was evident by formation of the C6–C7 bond-cleavage product 38 (20%)59 and the
tetracyclic byproduct 40 (20%). Formation of tetracycle 40 is consistent with a competing
loss of methanol to afford pyrrolopyrazinone 39, an observed intermediate, that prevents the
desired C-ring formation and permits C13 to engage the imidazolone.60 The observed lower
efficiency of the desired cyclization with 35 compared to 19 echoes the scarcity of natural
(–)-Agelastatin D (4) compared to other N-methyl agelastatin alkaloids.9,10,61
Furthermore, we have accessed the structures of the two newly isolated (–)-Agelastatins E
(5) and F (6) by their direct synthesis from (–)-Agelastatin A (1) and D (4), respectively
(Scheme 4). Heating a methanolic solution of (–)-Agelastatin A (1) with BrØnsted acid at 65
°C for 2 h afforded (–)-Agelastatin E (5) in 96% yield (Scheme 4).7 A synthetic sample of
(–)-Agelastatin F (6) was generated in 86% yield by bromination of (–)-Agelastatin D (4)
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under the optimal conditions described above for the synthesis of (–)-Agelastatin B (2),
thereby confirming its molecular structure.
Our biosynthetically inspired strategy for the advanced stage C-ring formation drew on the
intrinsic chemistry of our proposed pre-agelastatin intermediates for rapid generation of
molecular complexity, enabling a unified approach to all known agelastatin alkaloids.
Collectively, our observations hint at a plausible sequence of events for the biogenesis of the
alkaloids 1–6 (Scheme 1). For example, the C13-bromopyrrole and the imidazolinone
substructures (present in all agelastatins) were critical in the successful C-ring cyclization.
Treatment of the des-bromo derivative 41 under the optimized cyclization conditions did not
afford the desired C-ring due to a more facile conversion to pyrrolopyrazinone 42 (57%,
Scheme 5),62 suggesting a beneficial role for the allylic strain between the C13-bromine and
C6-methylene to restrict the C7-methine in a pseudo-equatorial conformation during the key
cyclization event.
Additionally, the aminoimidazole 43 failed to undergo the desired cyclization reaction due
to a more competitive pyrrolopyrazinone 44 formation (92%, Scheme 5), an observation we
attribute to the greater propensity of the aminoimidazolone substructure to remain
protonated and thus less nucleophilic under the reaction conditions.
Consequently, we suggest a higher probability for biosynthetic introduction of the C13-
bromopyrrole and imidazolone substructures prior to C-ring formation. Moreover, our
observations regarding the higher predisposition for the pre-agelastatin A derivative (+)-19,
to undergo C-ring formation as compared to the desmethyl derivative (+)-35 may suggest
predominant N1-methylation prior to C-ring cyclization in the biogenesis of the agelastatins.
The stereochemical outcome for the key C-ring cyclization is controlled by the C7-methine
to secure the desired thermodynamically favored C4-, C5-, and C8-stereocenters.
Specifically, the C5-center is controlled by the C4-stereochemistry to give a cis-fused CD-
ring system upon hydroxylation. It is conceivable that putative agelastatin biosynthetic
enzymes have evolved to enhance the innate stereoselectivity of compounds related to those
utilized in our synthesis.63 While our total syntheses of alkaloids 1–6 do not confirm our
hypothesis for their biogenesis, it is gratifying to have chemical validation for our proposed
mode and timing of bond and ring formations in the biosynthesis of these alkaloids.
Conclusions
We have completed the total syntheses of all known agelastatin alkaloids (1–6) through a
unified strategy inspired by our hypothesis for their biogenesis. Key features of our
syntheses include: 1) the concise multi-gram scale enantioselective synthesis of our
proposed “pre-agelastatin” derivatives, 2) the use of the bromopyrrole substructure to
suppress C7-deprotonation, 3) a versatile synthesis of imidazolone derivatives via a new
[4+1] annulation strategy, 4) the validation of our bioinspired 5-exo-trig advanced stage C-
ring formation, and 5) utilization of the intrinsic chemistry of plausible biosynthetic
intermediates for rapid generation of molecular complexity. The overall efficiency of our
strategy is highlighted by our 1.4 gram batch enantioselective synthesis of (–)-Agelastatin A
(1). With this most concise total chemical synthetic access to all natural agelastatin alkaloids
and related derivatives, studies aimed at probing their chemical and biological mode of
action are ongoing and will be the subject of forthcoming reports.
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55. For a previously described semi-synthesis of (−)-30 from (−)-5, see ref 7. Notably, we observed
that (−)-29 undergoes dehydration at a faster rater than (−)-5.
56. Treatment of either (−)-di-epi-agelastatin C (31) or (–)-Agelastatin C (3) with MeSO3H (10 equiv)
in D2O at 100 °C for 3 d, afforded a 1:1 equilibrium mixture of (−)-di-epi-agelastatin C (31) and
(–)-Agelastatin C (3) with quantitative deuterium incorporation at the C6-methylene as indicated
by 1H NMR analysis. See supporting information for details.
57. Direct comparison of the rates of deuterium incorporation between (+)-O-methyl-pre-agelastatin A
(19) and (+)-O-methyl-pre-agelastatin D (35) revealed that (+)-19 incorporates deuterium at the
C4-position 10 times faster than (+)-35.
58. Resubmission of (−)-O-methyl-di-epi-agelastatin D (36) to MeSO3H in H2O at reflux for 25 h
afforded (–)-Agelastatin D (4) in 68% yield.
59. C6–C7 bond fragmentation, requiring C5–C6 π-bond formation, is likely facilitated by diminished
allylic strain imposed by the N1–H intermediate 36 compared to N1–Me derivative 17.
60. 1H NMR monitoring of this reaction revealed the formation and slow consumption of 39. At lower
temperature (60 °C), 39 was recovered from the reaction mixture; its resubmission to the
cyclization conditions afforded 40 in 24% yield.
61. Neither the optical rotation nor the 13C NMR spectrum of agelastatin D was obtained in the
original isolation report as it was a minor component.
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62. The C8-hydroxy derivative of 41 accounted for approximately 20% of the mass balance after 20
min. Prolonged exposure of 41, the C8-hydroxy derivative of 41, or 42 to the reaction conditions
did not afford the desired cyclization.
63. The opposite C7-stereochemistry of (−)-cyclooroidin (10) compared to that of the agelastatins
entreats the possibility that downstream biosynthetic enzymes may preferentially bind and
consume derivatives of ent-cyclooroidin for the synthesis of the agelastatins.
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Fig. 1.
The molecular structures of all agelastatin alkaloids (1–6) and biogenetically related
naturally occurring simpler pyrrole-imidazole alkaloids (7–10).
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Scheme 1.
Our retrosynthetic analysis of (–)-Agelastatin A (1) inspired by our biosynthetic hypothesis
that involves intermediacy of pre-agelastatin A (16) in a final stage formation of the C-ring
and rapid introduction of the C4-, C5-, and C8-stereochemistry (16→1).
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Scheme 2.
Gram-scale enantioselective total synthesis of (–)-Agelastatin A (1) and elaboration to (–)-
Agelastatin B (2) and (–)-Agelastatin C (3). Reagents and conditions: (a) NBS, DTBMP,
THF (92%); (b) ClSO2NCO, MeCN, 0 °C; Na(Hg), NaH2PO4 (82%); (c) NaBH4 MeOH, 0
°C; TsOH•H2O, 23 °C (90%); (d) HSC6H4-p-Me, AlMe3, CH2Cl2, 0 °C (92%); (e) 27,
CuTC, THF, 50 °C (96%); (f) HCl (0.5N), MeOH, 65 °C (89%);
(g) cHx3SnCH2NH(CO)NHMe (33), CuTC, THF, 50 °C; HCl (0.5N), MeOH, 23 °C (58%);
(h) MeSO3H, H2O, 100 °C; MeOH (71% (2:1, (−)-1:(−)-29)); (i) MeSO3H, H2O, 100 °C;
MeOH (66% of (−)-1, and 30% of recovered (−)-29); (j) NBS, DTBMP, THF, H2O, 0 °C
(84%); (k) pyr., 115 °C (99%); (l) DMDO, acetone, H2O (98%); (m) Amberlyst 15, H2O,
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100 °C, 5 d (41% of (−)-3, and 42% of recovered (−)-31); NBS = N-bromosuccinimide,
DTBMP = 2,6-di-tbutyl-4-methylpyridine, TsOH = p-toluenesulfonic acid, CuTC =
copper(I)-thiophene-2-carboxylate, DMDO = dimethyldioxirane, pyr. = pyridine.
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Scheme 3.
Total synthesis of (–)-Agelastatin D (4). Reagents and conditions: (a) CuTC, THF, 50 °C;
(b) HCl (0.5N), MeOH, 23 °C (62% (2-steps)); (c) MeSO3H, H2O, 100 °C; HCl, MeOH
(26% (−)-4, 9% (−)-37, 20% 38, 20% (±)-40); CuTC = copper(I)-thiophene-2-carboxylate.
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Scheme 4.
Total synthesis of (–)-Agelastatin E (5) and (–)-Agelastatin F (6). Reagents and conditions:
(a) Amberlyst 15, MeOH, 65 °C (96%); (b) NBS, DTBMP, THF, H2O, 0 °C (86%).
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Scheme 5.
Key observations concerning our bioinspired C-ring synthesis strategy. Attempted
cyclization of A) desbromo-pre-agelastatin A (41) and B) imidazole derivative 43. Reagents
and conditions: (a) MeSO3H, H2O, 100 °C, 20 min (57%); (b) Dowex, H2O, 100 °C (92%).
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